Drug intelligence / Profile preview

sudapyridine + itraconazole

Development stage: Unknown
Lead developer: Guangzhou JOYO Pharma Co., Ltd
Modality: Small Molecules
Administration: Oral

Overview

**Sudapyridine + itraconazole** is a combination of two small molecule agents under investigation for the treatment of tuberculosis. Sudapyridine (WX-081) is a novel anti-mycobacterial agent currently in phase III clinical trials and designed as a derivative of bedaquiline. Itraconazole is a broad-spectrum triazole antifungal that inhibits fungal cell membrane synthesis by targeting lanosterol 14α-demethylase. The combination is being tested to evaluate efficacy against Mycobacterium tuberculosis, leveraging possible synergistic or additive effects.

Other names: sudapyridine + itraconazole

Targets

ATP SynthaseCYP51A1 (Sterol 14α-demethylase)

Beyond the preview

Go deeper on sudapyridine + itraconazole.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on sudapyridine + itraconazole.

Explore the full profile